BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...residual royalty interest in cystic fibrosis treatments from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) owned by the Cystic Fibrosis Foundation...
...PTZ-201 CARsgen Therapeutics Co. Ltd. Loyal Valley Capital Lilly Asia Ventures Shiyu Capital South China Venture Capital Royalty Pharma plc Vertex Pharmaceuticals Inc. Cystic Fibrosis Foundation DBV...
BioCentury | Oct 21, 2020
Finance

Oct. 20 Quick Takes: AbSci raises $65M; plus Aptinyx, Synspira and Aridis

...pain associated with diabetic peripheral neuropathy.CF Foundation investing in Synspira programsSynspira Therapeutics Inc. said the Cystic Fibrosis Foundation...
BioCentury | Aug 21, 2020
Finance

CF Foundation’s Longwood incubator fund to push early tech toward CF

...commits $20M to jump-start genetic therapies for cystic fibrosis  By stephen hansen, associate editor The Cystic Fibrosis Foundation’s...
...charity is hoping to partner with other VCs to broaden the early-stage CF development pipeline.The Cystic Fibrosis Foundation...
...launched last year that aims to develop therapies for those patients within the 10% (see “Cystic Fibrosis Foundation...
BioCentury | Aug 7, 2020
Finance

Aug. 6 Quick Takes: More pressure on China’s U.S. listings; busy Editas; Athenex bestows royalty on Sagard; Longwood, CFF launch incubator and more

...see “Sagard Gaining Healthcare Foothold Via Royalty Fund” ). CF Foundation, Longwood launch incubator The Cystic Fibrosis Foundation...
...Bonanos, Associate Editor BioCentury Staff EDIT-101, lca10, AGN-151587 Editas Medicine Inc. AbbVie Inc. Allergan plc Beam Therapeutics Inc. Tangen Biosciences Inc. Trobix Innovation Ltd. Cystic Fibrosis Foundation Longwood...
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

...led by Viking Global Investors. Also participating were new investors Amzak Health, Casdin Capital, the Cystic Fibrosis Foundation...
BioCentury | May 29, 2020
Finance

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

...antimicrobial drug Montana-based Microbion Corp. received up to $17.1 million in grants from CARB-X and Cystic Fibrosis Foundation...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

...of the disease, in large part because of R&D partnerships directed and funded by The Cystic Fibrosis Foundation...
BioCentury | Nov 2, 2019
Finance

American Cancer Society’s BrightEdge venture fund hoping to do well by doing good

...creating long-term financial stability for ACS, Bob Crutchfield, its managing director, told BioCentury. Unlike the Cystic Fibrosis Foundation...
BioCentury | Nov 1, 2019
Product Development

Vertex’s triple therapy will reshape the landscape of cystic fibrosis trials

...to upstage the small molecules with new modalities like mRNA or one-and-done curative approaches. The Cystic Fibrosis Foundation...
...to fund R&D therapies for patients whose genotypes aren’t treated by Vertex’s marketed drugs. (see “Cystic Fibrosis Foundation...
...no possibility of doing a long-term placebo. I think it would be unethical.” Michael Boyle, Cystic Fibrosis Foundation...
BioCentury | Oct 30, 2019
Company News

Cystic Fibrosis Foundation to invest $500M to support development of therapies for remaining 10% of CF patients

...Following the approval of Vertex’s triple therapy last week, the Cystic Fibrosis Foundation is launching a $500 million...
...on.” CFF is calling upon potential collaborators to submit proposals. Stephen Hansen, Associate Editor VX-445/tezacaftor/ivacaftor (VX-445/VX-661/VX-770) Vertex Pharmaceuticals Inc. Cystic Fibrosis Foundation...
Items per page:
1 - 10 of 260
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...residual royalty interest in cystic fibrosis treatments from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) owned by the Cystic Fibrosis Foundation...
...PTZ-201 CARsgen Therapeutics Co. Ltd. Loyal Valley Capital Lilly Asia Ventures Shiyu Capital South China Venture Capital Royalty Pharma plc Vertex Pharmaceuticals Inc. Cystic Fibrosis Foundation DBV...
BioCentury | Oct 21, 2020
Finance

Oct. 20 Quick Takes: AbSci raises $65M; plus Aptinyx, Synspira and Aridis

...pain associated with diabetic peripheral neuropathy.CF Foundation investing in Synspira programsSynspira Therapeutics Inc. said the Cystic Fibrosis Foundation...
BioCentury | Aug 21, 2020
Finance

CF Foundation’s Longwood incubator fund to push early tech toward CF

...commits $20M to jump-start genetic therapies for cystic fibrosis  By stephen hansen, associate editor The Cystic Fibrosis Foundation’s...
...charity is hoping to partner with other VCs to broaden the early-stage CF development pipeline.The Cystic Fibrosis Foundation...
...launched last year that aims to develop therapies for those patients within the 10% (see “Cystic Fibrosis Foundation...
BioCentury | Aug 7, 2020
Finance

Aug. 6 Quick Takes: More pressure on China’s U.S. listings; busy Editas; Athenex bestows royalty on Sagard; Longwood, CFF launch incubator and more

...see “Sagard Gaining Healthcare Foothold Via Royalty Fund” ). CF Foundation, Longwood launch incubator The Cystic Fibrosis Foundation...
...Bonanos, Associate Editor BioCentury Staff EDIT-101, lca10, AGN-151587 Editas Medicine Inc. AbbVie Inc. Allergan plc Beam Therapeutics Inc. Tangen Biosciences Inc. Trobix Innovation Ltd. Cystic Fibrosis Foundation Longwood...
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

...led by Viking Global Investors. Also participating were new investors Amzak Health, Casdin Capital, the Cystic Fibrosis Foundation...
BioCentury | May 29, 2020
Finance

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

...antimicrobial drug Montana-based Microbion Corp. received up to $17.1 million in grants from CARB-X and Cystic Fibrosis Foundation...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

...of the disease, in large part because of R&D partnerships directed and funded by The Cystic Fibrosis Foundation...
BioCentury | Nov 2, 2019
Finance

American Cancer Society’s BrightEdge venture fund hoping to do well by doing good

...creating long-term financial stability for ACS, Bob Crutchfield, its managing director, told BioCentury. Unlike the Cystic Fibrosis Foundation...
BioCentury | Nov 1, 2019
Product Development

Vertex’s triple therapy will reshape the landscape of cystic fibrosis trials

...to upstage the small molecules with new modalities like mRNA or one-and-done curative approaches. The Cystic Fibrosis Foundation...
...to fund R&D therapies for patients whose genotypes aren’t treated by Vertex’s marketed drugs. (see “Cystic Fibrosis Foundation...
...no possibility of doing a long-term placebo. I think it would be unethical.” Michael Boyle, Cystic Fibrosis Foundation...
BioCentury | Oct 30, 2019
Company News

Cystic Fibrosis Foundation to invest $500M to support development of therapies for remaining 10% of CF patients

...Following the approval of Vertex’s triple therapy last week, the Cystic Fibrosis Foundation is launching a $500 million...
...on.” CFF is calling upon potential collaborators to submit proposals. Stephen Hansen, Associate Editor VX-445/tezacaftor/ivacaftor (VX-445/VX-661/VX-770) Vertex Pharmaceuticals Inc. Cystic Fibrosis Foundation...
Items per page:
1 - 10 of 260